Latest Firebrick Pharma (ASX:FRE) News

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.